Puma Biotechnology (PBYI) Receivables - Other (2012 - 2019)

Puma Biotechnology's (PBYI) quarterly Receivables - Other came in at $9.9 million in Q1 2019, up 743.57% on a QoQ basis from $1.2 million in Q4 2018.

Puma Biotechnology (PBYI) Receivables - Other (2012 - 2019) Analysis & Trends

Puma Biotechnology (PBYI) has 5 years of Receivables - Other data on file, last reported at $9.9 million in Q1 2019.

Quarterly Receivables - Other changed N/A year-over-year to $9.9 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $9.9 million (changed N/A YoY) and the FY2018 annual result came in at $1.2 million, changed N/A from the prior year.
Receivables - Other rose to $9.9 million in Q1 2019, from $1.2 million in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $11.2 million in Q3 2018 to a low of $1.2 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Puma Biotechnology	451.24 Mn	357.33 Mn	44.03 Mn

Download Data